Keyphrases
Medical Therapy
100%
Heart Failure with Preserved Ejection Fraction (HFpEF)
100%
Standard of Care
22%
Clinical Benefit
22%
Pharmacological Therapy
22%
Attenuation
11%
Public Health Risk
11%
Clinical Trials
11%
Patients with Heart Failure
11%
Clinical Conditions
11%
Novel Agents
11%
Pathophysiology
11%
High Mortality
11%
Improved Survival
11%
Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i)
11%
Mortality Burden
11%
Morbidity Burden
11%
Cardiac Myosin Activator
11%
Novel Therapies
11%
High Morbidity
11%
Cardiac Remodeling
11%
Dilatation
11%
Cardiac Contractility
11%
Treatment Goals
11%
Sympathetic Nervous System
11%
Left Ventricular Remodeling
11%
Chronic Heart Failure
11%
Renin-angiotensin-aldosterone System
11%
Guideline-directed Medical Therapy
11%
European Society of Cardiology Guidelines
11%
Omecamtiv Mecarbil
11%
Soluble Guanylate Cyclase Stimulator
11%
Vericiguat
11%
HF Hospitalization
11%
Adverse Clinical Outcomes
11%
Improved A
11%
Angiotensin
11%
Medicine and Dentistry
Combination Therapy
100%
Heart Failure with Reduced Ejection Fraction
100%
Drug Therapy
22%
Heart Ventricle Remodeling
22%
Public Health
11%
Clinical Trial
11%
Heart Failure
11%
Pathophysiology
11%
Cardiology
11%
Cardiac Myosin
11%
Heart Muscle Contractility
11%
Sympathetic Nervous System
11%
Guanylate Cyclase Activator
11%
Omecamtiv Mecarbil
11%
Vericiguat
11%
Angiotensin
11%
Cotransporter
11%
Pharmacology, Toxicology and Pharmaceutical Science
Heart Failure with Reduced Ejection Fraction
100%
Combination Therapy
100%
Pharmacotherapy
22%
Heart Ventricle Remodeling
22%
Clinical Trial
11%
Heart Failure
11%
Cardiac Myosin
11%
Vericiguat
11%
Guanylate Cyclase Activator
11%
Omecamtiv Mecarbil
11%
Pathophysiology
11%
Angiotensin
11%
Cotransporter
11%